Free Trial
NASDAQ:VIRX

Viracta Therapeutics (VIRX) Stock Price, News & Analysis

$0.74
+0.01 (+1.38%)
(As of 05/24/2024 ET)
Today's Range
$0.66
$0.80
50-Day Range
$0.71
$1.17
52-Week Range
$0.43
$1.77
Volume
66,422 shs
Average Volume
54,424 shs
Market Capitalization
$28.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Viracta Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
784.4% Upside
$6.50 Price Target
Short Interest
Bearish
2.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of Viracta Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$2,486 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.06) to ($0.99) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.87 out of 5 stars

Medical Sector

657th out of 917 stocks

Pharmaceutical Preparations Industry

306th out of 423 stocks

VIRX stock logo

About Viracta Therapeutics Stock (NASDAQ:VIRX)

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

VIRX Stock Price History

VIRX Stock News Headlines

Oppenheimer Keeps Their Buy Rating on Viracta Therapeutics (VIRX)
RBC Capital Keeps Their Buy Rating on Viracta Therapeutics (VIRX)
VIRX Mar 2024 2.500 call
See More Headlines
Receive VIRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
5/25/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VIRX
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.50
High Stock Price Target
$11.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+784.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-51,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.14 per share

Miscellaneous

Free Float
35,074,000
Market Cap
$28.86 million
Optionable
Optionable
Beta
0.95
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Mark Andrew Rothera (Age 61)
    CEO, President & Director
    Comp: $365.03k
  • Dr. Susan Perrine M.D.
    Scientific Founder and Consultant
  • Dr. Ronald J. Berenson M.D. (Age 72)
    Co-Founder and Consultant
  • Mr. George Hillman
    Co-Founder
  • Dr. Thalia Papayannopoulou M.D.
    Co-Founder
  • Dr. Robert M. Williams Ph.D. (Age 69)
    Co-Founder
  • Dr. Douglas V. Faller M.D.
    Ph.D., Scientific Founder & Chairman of Scientific Advisory Board
  • Ms. Melody Burcar CPA (Age 41)
    M.B.A., Senior VP of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer
  • Dr. Ayman El-Guindy
    Chief Scientific Officer
  • Mr. Stewart M. Brown
    Senior VP of Legal Affairs & General Counsel

VIRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Viracta Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viracta Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VIRX shares.
View VIRX analyst ratings
or view top-rated stocks.

What is Viracta Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued 12-month price targets for Viracta Therapeutics' stock. Their VIRX share price targets range from $4.00 to $11.00. On average, they predict the company's share price to reach $6.50 in the next year. This suggests a possible upside of 784.4% from the stock's current price.
View analysts price targets for VIRX
or view top-rated stocks among Wall Street analysts.

How have VIRX shares performed in 2024?

Viracta Therapeutics' stock was trading at $0.57 at the beginning of the year. Since then, VIRX shares have increased by 28.9% and is now trading at $0.7350.
View the best growth stocks for 2024 here
.

When is Viracta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our VIRX earnings forecast
.

How were Viracta Therapeutics' earnings last quarter?

Viracta Therapeutics, Inc. (NASDAQ:VIRX) issued its earnings results on Thursday, March, 7th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.05.

How do I buy shares of Viracta Therapeutics?

Shares of VIRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VIRX) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners